Table 1.
Clinical and laboratory characteristics of controls and HIV-infected individuals.
| Control (n = 36) | HIV + (n = 30) | |
|---|---|---|
| Age (years) | 30 (27–35) | 45 (38–50)* |
| Gender (male) | 14 (38.8%) | 14 (46.6%) |
| TCD4+ cell count (per mL) | — | 526 (258–862) |
| Nadir TCD4+ | — | 243 (71–550) |
| HIV-1 Viral load (x 103 copies/mL) | — | Undetectable |
| Time since HIV diagnosis (months) | — | 114 (63–121) |
| cARV | — | 30 (100%) |
| NRTI + NNRTI | — | 18 (60%) |
| NRTI + PI/R | — | 9 (30%) |
| NRTI + INSTI | — | 3 (10%) |
| Platelet count (x 103) | 196 (153–238) | 205.8 (143–213) |
| APT (%) | 71 (67–87) | 85 (70–94) |
| PTT (Seconds) | 30 (28–32) | 29 (24–31) |
| INR | 1,18 (1,0–1,2) | 1,1 (1,0–1,2) |
Results are expressed as median and interquartile range (IQR). NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; INSTI, integrase inhibitor; APT, activated prothrombin time; PTT, partial thromboplastin time; INR, international normal ratio. *p < 0.05.